[go: up one dir, main page]

MX2019012007A - Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2. - Google Patents

Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2.

Info

Publication number
MX2019012007A
MX2019012007A MX2019012007A MX2019012007A MX2019012007A MX 2019012007 A MX2019012007 A MX 2019012007A MX 2019012007 A MX2019012007 A MX 2019012007A MX 2019012007 A MX2019012007 A MX 2019012007A MX 2019012007 A MX2019012007 A MX 2019012007A
Authority
MX
Mexico
Prior art keywords
making
processes
crystalline forms
mdm2 inhibitor
intermediates
Prior art date
Application number
MX2019012007A
Other languages
English (en)
Other versions
MX379872B (es
Inventor
R Mcgee Lawrence
Bio Matthew
Caille Sebastien
Cochran Brian
Fang Yuanqing
M Fox Brian
Vounatsos Filisaty
Wiedemann Sean
Wortman Sarah
S Lucas Brian
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019012007A publication Critical patent/MX2019012007A/es
Publication of MX379872B publication Critical patent/MX379872B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona procesos para fabricar ácido 2-((3R,5R,6S)-5-(3- clorofenil)-6-(4-clorofenil)-1-((S)-1-(isoprop ilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3- il)acético así como intermediarios y procesos para fabricar los intermediarios. También se proporcionan formas cristalinas del compuesto y los intermediarios.
MX2019012007A 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2 MX379872B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10
PCT/US2014/041594 WO2014200937A1 (en) 2013-06-10 2014-06-09 Processes of making and crystalline forms of a mdm2 inhibitor

Publications (2)

Publication Number Publication Date
MX2019012007A true MX2019012007A (es) 2019-11-11
MX379872B MX379872B (es) 2025-03-11

Family

ID=51063849

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012007A MX379872B (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
MX2015016856A MX2015016856A (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015016856A MX2015016856A (es) 2013-06-10 2014-06-09 Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2.

Country Status (38)

Country Link
US (10) US9376386B2 (es)
EP (2) EP3008039B1 (es)
JP (5) JP6998655B2 (es)
KR (4) KR20240159641A (es)
CN (3) CN105358530A (es)
AP (1) AP2015008891A0 (es)
AR (3) AR096582A1 (es)
AU (5) AU2014278428B2 (es)
BR (2) BR112015031004B1 (es)
CA (4) CA3200532A1 (es)
CL (3) CL2015003589A1 (es)
CR (2) CR20210290A (es)
CY (1) CY1123661T1 (es)
DK (1) DK3008039T3 (es)
EA (3) EA202091612A1 (es)
ES (1) ES2851023T3 (es)
HR (1) HRP20202065T1 (es)
HU (1) HUE053047T2 (es)
IL (4) IL297860A (es)
JO (2) JOP20200296A1 (es)
LT (1) LT3008039T (es)
MA (3) MA53572A1 (es)
MX (2) MX379872B (es)
MY (2) MY194848A (es)
NZ (1) NZ714821A (es)
PE (2) PE20210153A1 (es)
PH (2) PH12020550916A1 (es)
PL (1) PL3008039T3 (es)
PT (1) PT3008039T (es)
RS (1) RS61192B1 (es)
SG (2) SG11201509896VA (es)
SI (1) SI3008039T1 (es)
SM (1) SMT202100013T1 (es)
TN (1) TN2015000521A1 (es)
TW (3) TWI791153B (es)
UA (2) UA121301C2 (es)
UY (2) UY35605A (es)
WO (1) WO2014200937A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MX393610B (es) 2013-11-11 2025-03-24 Amgen Inc Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
AU2019273850B2 (en) * 2018-05-25 2024-11-14 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
CN112912080B (zh) 2018-08-31 2024-05-10 美国安进公司 用于制备mdm2抑制剂的方法
CN110963958B (zh) * 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021236474A1 (en) * 2020-05-22 2021-11-25 Merck Sharp & Dohme Corp. Novel processes for preparing conjugates of the il-2 protein
US20230313313A1 (en) 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
EP4382509A4 (en) * 2021-08-05 2025-08-27 Bio Pharm Solutions Co Ltd CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
US20250134877A1 (en) * 2021-09-09 2025-05-01 Kartos Therapeutics Methods of treating cancer dependent on myc gene expresssion
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
CH436295A (de) 1961-11-13 1967-05-31 Mcneilab Inc Verfahren zur Herstellung neuer 3-Morpholinone
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
ATE219077T1 (de) 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
DE69735710T2 (de) 1996-02-13 2007-03-29 Abbott Laboratories, Abbott Park Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
TR200000993T2 (tr) 1997-08-04 2000-12-21 Abbott Laboratories Endotelin antagonistleri.
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
WO2002042731A2 (en) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
WO2002060894A2 (en) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Sulfonamide lactam inhibitors of factor xa
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
CN1953965B (zh) 2004-05-18 2012-07-04 霍夫曼-拉罗奇有限公司 新型顺式咪唑啉类化合物
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) * 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
AU2005295441B2 (en) 2004-10-18 2009-04-23 Amgen, Inc. Thiadiazole compounds and methods of use
BRPI0607863B8 (pt) 2005-02-18 2021-05-25 Mitsubishi Pharma Corp sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
WO2006107860A2 (en) 2005-04-04 2006-10-12 Eisai Co., Ltd. Dihydropyridine compounds and compositions for headaches
WO2006131923A2 (en) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Novel salts of conjugated psychotropic drugs and processes of preparing same
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
EP2130822A1 (en) 2005-12-01 2009-12-09 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
EP1981884B1 (en) 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
MX2009000661A (es) 2006-07-19 2009-03-27 Univ Georgia Res Found Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion.
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CN101715453B (zh) 2007-03-23 2012-06-27 安姆根有限公司 杂环化合物及其应用
MX2009010050A (es) 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
US7919498B2 (en) 2007-03-23 2011-04-05 Amgen Inc. Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
EP2176238B1 (en) 2007-07-09 2012-04-18 AstraZeneca AB Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
JP5561702B2 (ja) 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Ｐｉ３キナーゼ調節剤および使用方法
MX2010003868A (es) 2007-10-09 2010-04-27 Hoffmann La Roche Cis-imidazolinas quirales.
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2222296A2 (en) 2007-12-26 2010-09-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
AU2009225984A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (en) * 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
AU2009294673B2 (en) 2008-09-18 2014-08-14 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
AU2010216239B2 (en) 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2011012037A (es) 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
UY32742A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
WO2010151737A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Heterocyclic compounds and their uses
UY32743A (es) 2009-06-25 2010-12-31 Amgen Inc Compuestos heterocíclicos y sus usos
CA2765817A1 (en) 2009-06-25 2010-12-29 Amgen Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
KR20120050492A (ko) 2009-08-26 2012-05-18 노파르티스 아게 테트라-치환된 헤테로아릴 화합물 및 ｍｄｍ2 및/또는 ｍｄｍ4 조절제로서의 그의 용도
CN102596981A (zh) * 2009-10-09 2012-07-18 尔察祯有限公司 抗菌氨基糖苷类类似物
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN103843105A (zh) * 2010-02-10 2014-06-04 摩奇有限公司(d/b/aVoxa) 暗视野像差矫正电子显微镜
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
DK2663309T3 (en) * 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
KR101921102B1 (ko) * 2011-04-28 2018-11-22 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 아조디카본아미드의 신규 제조법
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
WO2013049250A1 (en) 2011-09-27 2013-04-04 Amgen Inc. Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
JP6417338B2 (ja) 2013-02-19 2018-11-07 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
EP2970237B1 (en) 2013-03-14 2017-09-27 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
TW201922705A (zh) 2019-06-16
AU2014278428B2 (en) 2018-11-15
EA031254B1 (ru) 2018-12-28
EA202091612A1 (ru) 2020-10-05
MX2015016856A (es) 2016-04-07
HRP20202065T1 (hr) 2021-02-19
CL2015003589A1 (es) 2016-06-17
MX379872B (es) 2025-03-11
UA121301C2 (uk) 2020-05-12
CA3115609C (en) 2023-08-08
IL266504B (en) 2021-04-29
NZ753956A (en) 2020-12-18
TW202035370A (zh) 2020-10-01
AU2014278428A1 (en) 2015-11-26
BR122020003153B1 (pt) 2022-09-27
US20160287570A1 (en) 2016-10-06
AR119727A2 (es) 2022-01-05
PL3008039T3 (pl) 2021-04-19
TWI698428B (zh) 2020-07-11
EA201592305A1 (ru) 2016-05-31
US20160264526A1 (en) 2016-09-15
CA2914723C (en) 2021-06-15
CL2019000056A1 (es) 2019-05-03
MY194848A (en) 2022-12-19
JP2021130685A (ja) 2021-09-09
JP2025084856A (ja) 2025-06-03
JP2016528179A (ja) 2016-09-15
CY1123661T1 (el) 2022-03-24
TWI649306B (zh) 2019-02-01
CA2914723A1 (en) 2014-12-18
US20160289243A1 (en) 2016-10-06
CR20210290A (es) 2021-07-23
WO2014200937A1 (en) 2014-12-18
LT3008039T (lt) 2021-01-25
CL2021000566A1 (es) 2021-09-03
IL297860A (en) 2023-01-01
HUE053047T2 (hu) 2021-06-28
EP3008039A1 (en) 2016-04-20
IL281807A (en) 2021-05-31
TN2015000521A1 (en) 2017-04-06
US20230301974A1 (en) 2023-09-28
CN105358530A (zh) 2016-02-24
JO3768B1 (ar) 2021-01-31
AU2022271425B2 (en) 2024-06-13
JP2020147573A (ja) 2020-09-17
US9623018B2 (en) 2017-04-18
KR20230019216A (ko) 2023-02-07
US9376386B2 (en) 2016-06-28
US20200281912A1 (en) 2020-09-10
US20160289178A1 (en) 2016-10-06
SG11201509896VA (en) 2016-01-28
AU2020267169B2 (en) 2022-08-25
AU2022271425A1 (en) 2022-12-22
UY35605A (es) 2015-01-30
US20180092898A1 (en) 2018-04-05
IL281807B (en) 2022-12-01
JP7263439B2 (ja) 2023-04-24
BR112015031004B1 (pt) 2022-09-20
AU2024216533A1 (en) 2024-09-19
MA53572A1 (fr) 2021-10-29
CR20160010A (es) 2016-02-04
AR132854A2 (es) 2025-08-06
UY40179A (es) 2023-04-14
BR112015031004A2 (pt) 2020-05-12
AU2018260844B2 (en) 2020-08-13
MA43288B1 (fr) 2020-10-28
SMT202100013T1 (it) 2021-03-15
AU2020267169A1 (en) 2020-12-03
CA3200532A1 (en) 2014-12-18
CN110003092A (zh) 2019-07-12
KR20240159641A (ko) 2024-11-05
PE20160113A1 (es) 2016-03-03
PH12015502705B1 (en) 2022-04-27
US9855259B2 (en) 2018-01-02
PH12015502705A1 (en) 2016-03-14
TWI791153B (zh) 2023-02-01
IL266504A (en) 2019-07-31
CN110627708A (zh) 2019-12-31
JOP20200296A1 (ar) 2017-06-16
US20220280496A1 (en) 2022-09-08
EP3805232A1 (en) 2021-04-14
PT3008039T (pt) 2021-01-13
DK3008039T3 (da) 2021-01-04
KR20210121270A (ko) 2021-10-07
US9801867B2 (en) 2017-10-31
SI3008039T1 (sl) 2021-03-31
MA43288A1 (fr) 2020-04-30
UA129695C2 (uk) 2025-07-09
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
PH12020550916A1 (en) 2024-03-25
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
AU2018260844A1 (en) 2018-11-22
PE20210153A1 (es) 2021-01-26
US20140364455A1 (en) 2014-12-11
JP6998655B2 (ja) 2022-02-04
SG10201801402XA (en) 2018-04-27
EP3008039B1 (en) 2020-11-11
MY205257A (en) 2024-10-09
CA3115609A1 (en) 2014-12-18
US9757367B2 (en) 2017-09-12
IL281807B2 (en) 2023-04-01
AP2015008891A0 (en) 2015-11-30
US20160289190A1 (en) 2016-10-06
CA3201958A1 (en) 2014-12-18
IL242622B (en) 2019-06-30
JP2023089126A (ja) 2023-06-27
JP6891322B2 (ja) 2021-06-18
ES2851023T3 (es) 2021-09-02
EA201891642A1 (ru) 2019-08-30
NZ714821A (en) 2020-10-30
AR096582A1 (es) 2016-01-20
IL242622A0 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
MX2019012007A (es) Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
SG10201903532XA (en) 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MY177290A (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
GB201114389D0 (en) Novel compounds
IL234966A0 (en) Crystal forms of (4-(s-amino-4)-1)-n-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo [3,2-d]pyrimidin-4-yl)piperidine-4-carboxamide
IN2013MU00916A (es)
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
MX2023015251A (es) Procesos para preparar un inhibidor de mdm2.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR
MX2014002343A (es) Inhibidores de parp.